Abbott Laboratories (NYSE:ABT) Price Target Lowered to $138.00 at Evercore ISI

Abbott Laboratories (NYSE:ABT) had its target price decreased by investment analysts at Evercore ISI from $144.00 to $138.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the healthcare product maker’s stock. Evercore ISI’s price target would indicate a potential upside of 27.19% from the company’s previous close.

Several other brokerages have also recently weighed in on ABT. Weiss Ratings restated a “buy (b-)” rating on shares of Abbott Laboratories in a report on Monday, December 29th. Barclays raised their target price on Abbott Laboratories from $162.00 to $169.00 and gave the stock an “overweight” rating in a research note on Monday, January 5th. Raymond James Financial boosted their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Daiwa Capital Markets raised their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 21st. Finally, Sanford C. Bernstein boosted their target price on shares of Abbott Laboratories from $150.00 to $154.00 and gave the company an “outperform” rating in a report on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $146.22.

Abbott Laboratories Trading Down 10.1%

Shares of ABT stock opened at $108.50 on Friday. Abbott Laboratories has a fifty-two week low of $105.78 and a fifty-two week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock’s fifty day moving average is $125.23 and its two-hundred day moving average is $128.54. The firm has a market capitalization of $188.67 billion, a P/E ratio of 13.60, a PEG ratio of 2.00 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The company’s quarterly revenue was up 4.4% compared to the same quarter last year. During the same period in the prior year, the business earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Abbott Laboratories

A number of large investors have recently modified their holdings of ABT. Brighton Jones LLC increased its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares in the last quarter. Sivia Capital Partners LLC increased its stake in Abbott Laboratories by 3.5% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock valued at $648,000 after purchasing an additional 162 shares in the last quarter. Signet Financial Management LLC raised its holdings in Abbott Laboratories by 6.5% during the second quarter. Signet Financial Management LLC now owns 3,066 shares of the healthcare product maker’s stock worth $417,000 after purchasing an additional 188 shares during the last quarter. McAdam LLC increased its stake in shares of Abbott Laboratories by 15.7% during the 2nd quarter. McAdam LLC now owns 2,780 shares of the healthcare product maker’s stock worth $378,000 after purchasing an additional 377 shares in the last quarter. Finally, Register Financial Advisors LLC lifted its stake in Abbott Laboratories by 49.5% in the 2nd quarter. Register Financial Advisors LLC now owns 3,590 shares of the healthcare product maker’s stock valued at $488,000 after buying an additional 1,188 shares in the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Several sell?side analysts kept constructive ratings and still see meaningful upside — Piper Sandler cut its price target to $135 but remains “overweight,” and BTIG trimmed its target to $140 while keeping a “buy” call, signaling continued analyst confidence despite the pullback. Benzinga
• Positive Sentiment: Med tech (devices) and Established Pharmaceuticals delivered strong growth (double?digit devices, mid?single to high single pharma), which management says helped offset weakness in other segments and supports the company’s multi?year growth thesis. Blockonomi
• Positive Sentiment: Market commentators view the pullback as a potential buying opportunity for long?term investors because Abbott remains a cash?generative Dividend King with capacity for buybacks and continued margin improvement. MarketBeat
• Neutral Sentiment: Adjusted EPS of $1.50 matched consensus, showing underlying earnings resilience even as revenues lagged; GAAP results included items that lowered headline net income. Press Release
• Neutral Sentiment: Company guidance: Q1 2026 adjusted EPS of $1.120–1.180 (below the ~1.20 consensus) and FY 2026 adjusted EPS of $5.55–5.80 (around consensus). Guidance tempered near?term expectations but keeps mid/longer?term growth intact. Press Release
• Negative Sentiment: Revenue missed Street estimates (~$11.46–11.5B reported vs. ~$11.8–11.9B expected); the Nutrition business declined sharply (near?9% year?over?year) and Diagnostics weakened (lower COVID testing and volatility), which triggered the market sell?off. Reuters Blockonomi
• Negative Sentiment: Unusual bearish positioning: intraday put option volume spiked sharply, indicating heavy hedging or speculative bearish bets that can amplify downward price moves. (Reported market activity)
• Negative Sentiment: Regulatory/legal overhang: documents show India regulators are scrutinizing supply of a codeine?based cough syrup tied to abuse investigations, introducing potential reputational and compliance risk. Reuters

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.